{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:41:16Z","timestamp":1790185276521,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Deutsche Krebshilfe e.V."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ejca.2012.11.010","type":"journal-article","created":{"date-parts":[[2012,12,19]],"date-time":"2012-12-19T15:41:00Z","timestamp":1355931660000},"page":"1346-1355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia \u2013 Long-term results of trial ALL-REZ BFM P95\/96"],"prefix":"10.1016","volume":"49","author":[{"given":"Cornelia","family":"Eckert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"von Stackelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W.L.","family":"Groeneveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klingebiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schrappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Henze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.11.010_b0005","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1470-2045(08)70229-8","article-title":"Bone-marrow relapse in paediatric acute lymphoblastic leukaemia","volume":"9","author":"Bailey","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.11.010_b0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2141.2005.05773.x","article-title":"Childhood acute lymphoblastic leukaemia and relapse","volume":"131","author":"Gaynon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2012.11.010_b0015","series-title":"Treatment of acute leukemias. New directions for clinical research","article-title":"Treatment of relapsed acute lymphoblastic leukemia","author":"Henze","year":"2002"},{"key":"10.1016\/j.ejca.2012.11.010_b0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mpo.2950210703","article-title":"Superior prognosis in combined compared to isolated bone marrow relapses in salvage therapy of childhood acute lymphoblastic leukemia","volume":"21","author":"Buhrer","year":"1993","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ejca.2012.11.010_b0025","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood.V78.5.1166.1166","article-title":"Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group","volume":"78","author":"Henze","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0030","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.2009.25.1983","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.010_b0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2141.2000.01891.x","article-title":"The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study","volume":"108","author":"Lawson","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2012.11.010_b0040","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/leu.2009.132","article-title":"\u2018Allogeneic marrow transplantation in children with acute leukemia: a practice whose time has gone\u2019: twenty years later","volume":"23","author":"Pinkel","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0045","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1200\/JCO.2008.20.8934","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.010_b0050","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0055","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer \u2013 Childhood Leukemia Cooperative Group","volume":"339","author":"Cave","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2012.11.010_b0060","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0065","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2002-01-0006","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0070","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","article-title":"Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"99","author":"Dworzak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0075","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.11.010_b0080","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0140-6736(01)06355-3","article-title":"Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia","volume":"358","author":"Eckert","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.11.010_b0085","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/sj.leu.2403283","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0090","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: a Children\u2019s Oncology Group Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.010_b0095","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V101.10.3835","article-title":"Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis","volume":"101","author":"Borgmann","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-2141.2008.07499.x","article-title":"Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria \u2013 a population-based report of the Austrian Berlin\u2013Frankfurt\u2013Munster (BFM) Study Group","volume":"144","author":"Reismuller","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2012.11.010_b0105","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.1996.14.10.2812","article-title":"Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin\u2013Frankfurt\u2013Munster Relapse Study Group","volume":"14","author":"Buhrer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.11.010_b0110","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/sj.leu.2400887","article-title":"Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations","volume":"11","author":"Langerak","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/sj.leu.2401245","volume":"13","author":"Pongers-Willemse","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0120","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1182\/blood.V93.12.4079","article-title":"Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage","volume":"93","author":"Szczepanski","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0125","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood-2003-08-2952","article-title":"Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells","volume":"103","author":"Szczepanski","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2012.11.010_b0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0009-8981(91)90247-A","article-title":"Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders","volume":"198","author":"van Dongen","year":"1991","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejca.2012.11.010_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0009-8981(91)90246-9","article-title":"Analysis of immunoglobulin and T cell receptor genes. Part I: basic and technical aspects","volume":"198","author":"van Dongen","year":"1991","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejca.2012.11.010_b0140","first-page":"175","article-title":"Real-time PCR to detect minimal residual disease in childhood ALL","volume":"91","author":"Eckert","year":"2004","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.ejca.2012.11.010_b0145","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/sj.leu.2403103","article-title":"Comparison between TaqMan and LightCycler technologies for quantification of minimal residual disease by using immunoglobulin and T-cell receptor genes consensus probes","volume":"17","author":"Eckert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0150","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0155","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.ejca.2012.11.010_b0160","series-title":"The statistical analysis of failure time data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.ejca.2012.11.010_b0165","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.11.010_b0170","series-title":"Statistical models in epidemiology","author":"Clayton","year":"2005"},{"key":"10.1016\/j.ejca.2012.11.010_b0175","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/leu.2011.227","article-title":"ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy","volume":"26","author":"Bhojwani","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ejca.2012.11.010_b0180","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/asheducation-2002.1.162","article-title":"Acute lymphoblastic leukemia","author":"Hoelzer","year":"2002","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ejca.2012.11.010_b0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.leu.2402019","article-title":"MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen","volume":"15","author":"zur Stadt","year":"2001","journal-title":"Leukemia"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912008957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912008957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:19:00Z","timestamp":1760732340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912008957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0959804912008957"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.11.010","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia \u2013 Long-term results of trial ALL-REZ BFM P95\/96","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2012.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}